Skip to content

Study of Efficacy, Safety and Tolerability of Na-Picosulphate in patients requiring anorectal surgery

Assessment of Efficacy, Tolerability and Safety of Cremalax® (Na Picosulphate 10mg) in Bowel Preparation Needed in Patients Undergoing Gastrointestinal OR Ano-rectal Surgery: A Prospective, Non-Comparative Study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/09/007292
Enrollment
100
Registered
2016-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients requiring bowel preparation for gastrointestinal or anorectal surgery

Interventions

Intervention1: Na Picosulphate: 10 mg Oral Tablet Intervention2: sodium Picosulphate: 10 mg oral tablet of sodium picosulphate Intervention3: Sodium picosulphate: 10mg oral tablet single dose at bedti

Sponsors

VYAS SURGERY
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male or female patients between 18 and 65 years of age 2. Posted for any GI surgery or ano-rectal Surgery and require bowel preparation as per PI discretion (elective procedure) 3. Patients willing to sign the written informed consent form Willing and able to understand and comply with all study requirements

Exclusion criteria

Exclusion criteria: 1. Patients having known hypersensitivity to Na Picosulphate or any of the excipients of product (Tablet Cremalax®) 2. Pregnant and lactating women 3. Patients undergoing emergency surgical procedures 4. Evidence of structural abnormality of the gastrointestinal tract or diseases/conditions that affect bowel transit 5. History of bowel obstruction, symptomatic gallbladder disease, suspected sphincter of Oddi dysfunction, or abdominal adhesions 6. Patients with any cardiac, renal, hepatic, neurological disorders, or any chronic illness 7. Evidence of cathartic colon or history of laxative abuse 8. Any systemic condition which would call for avoidance/non-use of stimulant laxatives 9. Any other condition, which in the opinion of the clinician/investigator, could interfere significantly with the treatment and assessment process 10. Use of any investigational therapy within 30 days prior to randomization 11. Patients not willing to provide written informed consent

Design outcomes

Secondary

MeasureTime frame
Difficulty in bowel handlingTimepoint: Day 2 (operative day);Operative field during surgeryTimepoint: Day 2 (operative day);Patient satisfaction for bowel evacuationTimepoint: Day 2 (operative day)

Primary

MeasureTime frame
The efficacy of bowel preparation assessed by the surgeon during the intra-operative period (during surgery) on the basis of a 4-point likert scale.Timepoint: Day 2 (operative day)

Countries

India

Contacts

Public ContactDr Dipak Vyas

VYAS SURGERY

drdipakvyas@gmail.com9821018412

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026